NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹185.00
- Market cap
- ₹205.7 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.3×Sector 46.1×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited has scheduled its 3rd Annual General Meeting for August 27, 2026, to be conducted through video conferencing for ordinary business transactions.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.